retatrutide phase 2 results obesity nejm 2023 Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people 🤔 Adults with type 2

Research Overview Retatrutide demonstrates a broad spectrum of biological activity, including modulation of appetite, glucose metabolism, and gastrointestinal motility

The switching between GLP-1 peptides guide covers transition protocols, though specific retatrutide switching data is limited to clinical trial enrollment procedures

Lastly, for those who are eligible, metabolic/bariatric surgery should remain part of the conversation, as it is one of the most effective and durable obesity treatments we have

Maandelijkse injecties als informeel onderhoud passen daar niet in

A major concern with the use of GLP-1 RAs has been their potential association with an increased risk of pancreatic cancer [10]